Articles from Arisan Therapeutics, Inc.

Arisan Therapeutics Selected for NIAID Contract Award to Develop a Therapeutic Small Molecule Viral Entry Inhibitor as a Medical Countermeasure for Filovirus Infection

Contract Valued at Up to $24 million Supports IND-Enabling Studies for Arisan’s Lead Candidate with Demonstrated Activity Against Multiple Ebolaviruses

By Arisan Therapeutics, Inc. · Via GlobeNewswire · August 13, 2026